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Abstract
Despite major expansions of evidence-based treatments of common mental disorders in recent
decades, especially antidepressant medication, the point prevalence of depression has not
decreased; instead it probably increased in young adults. We question whether antidepressants
(AD)-monotherapy and low-fidelity-to-guideline psychological treatment (PT) might have no
effect or even adverse effects in some patients and contexts that dilute the benefits of treatment at
the population level, making it harder for population-based studies to detect treatment-driven
prevalence reductions. Randomized Clinical Trial (RCT)s have not identified these effects
because AD-monotherapy and low-fidelity PT are uncommon in RCTs where treatment pro-
tocols are specified and carefully monitored, unlike treatment in real-world settings. Second,
RCTs may have missed the bigger picture of ultimate outcomes due to too short follow-ups. We
elaborate two mechanisms through which AD-monotherapy and low-fidelity PT could produce
adverse effects on long-term illness course. Bothmechanisms are speculative andwe outline how
to test.
Major depressive disorder is a common, highly heterogeneous disorder. To reduce its enormous
burden [1], Western countries have expanded their mental health expenditures in specialty and
primary care settings since the 1980s [2], providing more treatment for more people, primarily
with antidepressants (AD) and, to a lesser extent, psychological treatments (PTs) [3,4]. Both
Antidepressant (AD)s and PTs are well-established, evidence-based treatments with roughly
similar modest short-term efficacy. Surprisingly, the point-prevalence of depression in the
general population has not decreased since the wide-scale use of AD [5]; instead, the prevalence
has probably increased, particularly in young people [6]. In addition, the prevalence of recurrent-
chronic and treatment-resistant depression seems to have risen [7]. One obvious explanation for
this “treatment-prevalence paradox” is increased first incidence, offsetting a treatment-driven
prevalence drop. But population-based incidence studies do not find such an increase [4,8].What
else could explain the paradox?
Explaining the Treatment-Prevalence Paradox
We question whether AD-monotherapy and low-fidelity-to-guideline PT might have no effect or
even adverse effects in some patients and contexts that dilute the benefits of treatment at the
population level, making it harder for population-based studies to detect treatment-driven
prevalence reductions. The hypothesized mechanisms through which AD-monotherapy and
low-fidelity PT could produce adverse effects on long-term illness course include Loss of Agency
[9] and Oppositional Perturbation [10] or Tolerance [11,12]. Both mechanisms are speculative
and need rigorous testing. RCTs have not identified these effects because AD-monotherapy and
low-fidelity PT are uncommon in RCTs where treatment protocols are specified and carefully
monitored, unlike treatment in real-world settings. In addition, AD-withdrawal studiesmay have
missed the bigger picture of improved ultimate outcomes, due to misinterpreted withdrawal
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Loss of Agency and Self-Help Activities
Loss of Agency refers to loss of self-efficacy, problem solving, and
other self-help activities that normally benefit recovery [9].Without
treatment, depressed people often engage independently in self-
help strategies, such as exercising, increasing pleasant activities,
reducing stress, and meditation [15]. These self-help strategies can
have two benefits. First, self-help activities can be therapeutic on
their own. Second, these activities may empower people to believe
in their own “agency” and “self-efficacy” for coping with depression
and underlying problems. Successful experiences provide individ-
uals with a greater sense of their own abilities, rather than feeling
broken and dependent on others ormedication to fix them [16]. For
example, wait-list controls do worse than other untreated subjects,
likely because, while awaiting treatment, people do not do the
things that they might otherwise do to feel better [17]. If people
on AD-monotherapy or low fidelity PT avoid or reduce self-help
activities, the benefits of treatment may be more than offset by
the loss of agency. Although exact data on the prevalence of
AD-monotherapy and low fidelity PT are lacking, there is ample
evidence of major treatment quality gaps [18].
According to the “network hypothesis” of depression, AD may
act by enhancing neuronal plasticity, which allows environmental
inputs to modify the neuronal networks to better fine tune the
individual to the outside world [19]. Recent observations in the
visual cortex directly support this idea [20]. This suggests that
antidepressant drugs should not be used alone, but should be
combined with interventions to guide the plastic networks within
the brain by providing appropriate environmental input (e.g.,
behavioral activation and meditation).
The risk of Loss of Agency may be substantial for AD-
monotherapy and low-fidelity PT provided without forms of
empowerment. The counterproductive effects probably depend
on provider characteristics, patient’s premorbid personality, and
contextual factors. Nowadays, more than 80% of Selective Seroto-
nin Reuptake Inhibitor (SSRI) prescriptions are written by General
practitioners (GP)s, who may have fewer empowering strategies
in their armamentarium or time to implement those. People in
disadvantaged communities might thus be deprived twice over
because they tend to receive more AD-monotherapy and less
rigorous PT treatment compared to the more comprehensive ser-
vice delivery of combined AD and empowering psychotherapy in
affluent areas [9].
Oppositional Perturbation and Symptom-Return
Oppositional perturbation refers to the AD-induced state of built-up
perturbation in homeostatic monoamine regulatory mechanisms
[10,12]. AD drive up the levels of neurotransmitters in the synapse.
According to this theory, in brief, underlying homeostatic mecha-
nisms are hypothesized to respond by shutting down synthesis
presynaptically and reducing sensitivity post-synaptically, which
establishes homeostatic regulation dependent on the ongoing intake
of medication. Therefore, this process is expected to create a persis-
tent state of perturbation. It has been proposed that, in a sense, AD
“hijack” the homeostatic monoamine regulatory mechanisms. How-
ever, this AD-driven perturbation “bounces back” when AD are
discontinued, and might overshoot the normal balance of mono-
amine storage and release, increasing the risk for symptom return
compared to spontaneous remission. Importantly, direct evidence
for oppositional perturbation is lacking, but the overshoot appears
proportional to the extent that the class of AD perturbs the
underlying neurotransmitter systems and corresponds with the like-
lihood of symptom return once AD are discontinued [10,12].
Some puzzling AD-related observations feed the idea of opposi-
tional perturbation. First, the excess risk of symptom-return in
remitted patients after AD discontinuation relative to that in remit-
ted patients after Cognitive Behavioral Therapy (CBT) discontinu-
ation [21] andADcontinuation [22]. The excess risk has usually been
interpreted as indicating that AD’s beneficial effects end at discon-
tinuation. This interpretation is based on the plausible assumption
that AD exposure is benign and has no lingering negative effects.
Although to some extent, the observed excess riskmay also be due to
misinterpreted withdrawal symptoms being classified as relapse/
recurrence [13], this is unlikely the whole story given that the excess
risk in the placebo-substitution arm persists 3–6months after dis-
continuation [22]. Oppositional perturbation suggests an alternative
explanation: the as prophylactic interpreted effects of CBT and
AD-continuation may be (partly) deceptive because instead there
could be an increased risk of relapse/recurrence due to AD treatment
(i.e., oppositional perturbation) that subsequent discontinuation
unveils.
Second, some AD trials showed stepwise loss of effectiveness
[23]. Bosman’s review of 10 studies examining failure to respond
upon resumption of previously effective AD after a period of nonuse
(tachyphylaxis) found that 16.5% of the 394 remitted patients who
restarted AD after their symptoms returned experienced failure to
respond (range 3.8–42.9%). Tachyphylaxis occurred in all
AD-classes and has not been observed for CBT [24]. Although these
nonresponders may alternatively be the patients who have had a
placebo-response earlier, tachyphylaxis could also be due to opposi-
tional perturbation with possible cumulative effects of agency loss,
especially in patients on AD-monotherapy.
Third, risk of symptom-return during long-term AD is substan-
tial. Multiple studies report 3-year cumulative risks exceeding 40%
[25]. The risk is particularly high among patients with residual
symptoms after acute treatment [26]. A variety of factors may drive
symptom-return during maintenance AD, including suboptimal
compliance and increased environmental stress. However, in
addition, “loss of protection” in patients on AD-monotherapy
(i.e., without empowerment), speculatively, might also reflect loss
of agency and/or oppositional perturbation. Some authors even
speculated that “tardive dysphoria” could develop in some predis-
posed individuals with prolonged AD-treatment [7].
How to Investigate the Hypotheses
Given the aforementioned uncertainties, the rather alarming fea-
tures of both loss of agency and oppositional perturbation, still
without empirical investigation, urgently require research to quan-
tify these effects. Acknowledging formidable feasibility and ethical
issues (which cannot be elaborated here), the schematic RCT
(Figure 1) enables their investigation. AD-free depressed individ-
uals are randomized into five arms: “AD-monotherapy,” “AD-
plus” (AD supplemented with an agency-enhancing/empowering
component), “CBT,” “pill-placebo” (PLA), and Control (ethically
acceptable treatment-on-demand group [27]). Patients in all arms
are monitored for at least 2 years and anyone who does not show a
minimum amount of improvement is considered to be “nonre-
sponsive” and is pulled from the trial, while research assessments
continue to monitor treatment and course. Later, AD discontinu-
ation should be very gradual with careful assessments to reduce risk
of misclassification of withdrawal symptoms as relapse/recurrence.
The accompanying text in Figure 1 details the critical comparisons.
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Comparing the long-term outcome of AD, CBT, and PLA is also
informative because AD and CBT can innovatively be compared
with the baseline of the PLA arm (lacking a specific AD or CBT
treatment mechanism). This will address whether CBT truly has an
enduring effect after discontinuation in patients remitted on CBT
or merely appears so in comparison to possible adverse effects of
AD after discontinuation in patients remitted on AD. The design
also permits estimation of the magnitude of spontaneous remission
(Control), nonspecific treatment effects (PLA vs. control), and
treatment-specific effects (AD vs. PLA and CBT vs. PLA) in both
short- and long-term outcomes.
Conclusion
The hypothesized mechanisms of loss of agency and oppositional
perturbation, together with AD-monotherapy and low-fidelity PT,
might contribute to counterproductive effects on long-term illness
course but need thorough empirical testing. If present, this would
dilute the beneficial impact of guideline-consistent treatment at
the population level, which could help explain the treatment-
prevalence paradox. Given their public health potential, it is impor-
tant to urgently investigate loss of agency and oppositional pertur-
bation, which currently are alarming but so-far speculative
hypotheses that have not been investigated.
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